Gilmore O’Neill: So with regard to the sickle cell data, again we were very encouraged by the initial clinical data, which were consistent with our preclinical data in demonstrating both impacts, robust effects on fetal hemoglobin and in the resolution of anemia. And we are looking forward and confident, we would see replication in subsequent patients for that data set and look forward to sharing updates in the middle and at the end of this year. And then with regard to reorganization, we have largely completed that reorganization. I think the critical element of the reorganization that is outstanding is the hiring of our chief scientific officer. I have already talked a little bit about the characteristics, traits, qualities we are looking for in that person leading forward. But the good news is that the discovery development, other functional components of the organization have good leadership and are already moving forward in the execution of our new strategy.
Greg Harrison: Great, that is helpful. thanks for taking the questions.
Operator: Our next question is Yanan Zhu with Wells Fargo. Please proceed.
Yanan Zhu: Hi, thanks for the questions. Have you dozed the third patient in the sickle cell trial yet? That is the first question. And at what point along the date of generation process from the sickle cell trial, do you plan to reach out and have a discussion with the regulator about the path forward for EDIT-301? And lastly, is the 301s manufacturing process carried out with a commercial grade process. And i.e., with some kind of bridging needed if it is not that kind of a process currently.
Gilmore O’Neill: Thanks very much Yanan. Baisong could you just sort of capitulate the update?
Baisong Mei: Yes. So thanks for your question, and I will get two first two questions. I will let Gilmore you answer the question about the manufacturer in there too. So, yes, and then we actually — we did dose the third patient and started – as we mentioned that start the parallel dosing for the patients. And regarding the registration of path forward, we will discuss with health authority to finalize that data package required for registration, and we will share more data when the time is appropriate.
Gilmore O’Neill: Thanks very much Baisong. With regard to our 301 process, the good news is that the – certainly on the potency matrix area, we have actually been very successful and ensuring that the patients that we are currently dosing in RUBY will be able to support a marketing application. With regard to the refinements and agreed final commercial process that will be something that we will update you obviously at a time that is appropriate and obviously we can include more details.
Yanan Zhu: Great. Thanks for the color.
Operator: Our next question is from Gena Wang with Barclays. Please proceed.
Gena Wang: Thank you. I have three quick questions. The first one is regarding the shoreline deal. Can you remind us the deal term and the economics, and when do you expect the transaction to be closed, does your cash guidance taking to consideration of impact from the deal? And that is a first question.
Gilmore O’Neill: Thanks, Gena. You are very good. You are going to keep them. That is great. So we don’t have to track them all. So with regard to the Shoreline deal, we didn’t actually disclose the numbers in the economics. We did receive an upfront, we are eligible for future development and commercial milestones and royalty payments with the advance of the assets, the indeed that the – those – the impact in the financials is actually included or has been considered. So that is I think the first question.
